Drug Approval | June 26, 2025
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Subscribe To Our Newsletter & Stay Updated
